Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Antiproliferative Effect of a Novel 4,4'-Disulfonyldiarylidenyl Piperidone in Human Colon Cancer Cells.

Prabhat AM, Kuppusamy ML, Bognár B, Kálai T, Hideg K, Kuppusamy P.

Cell Biochem Biophys. 2019 Mar;77(1):61-67. doi: 10.1007/s12013-018-0862-5. Epub 2018 Dec 14.

PMID:
30552554
2.

Oligomerization Alters Binding Affinity Between Amyloid Beta and a Modulator of Peptide Aggregation.

Hilt S, Rojalin T, Viitala T, Koivuniemi A, Bunker A, Hogiu SW, Kálai T, Hideg K, Yliperttula M, Voss JC.

J Phys Chem C Nanomater Interfaces. 2017 Nov 2;121(43):23974-23987. doi: 10.1021/acs.jpcc.7b06164. Epub 2017 Oct 10.

3.

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Madan E, Parker TM, Bauer MR, Dhiman A, Pelham CJ, Nagane M, Kuppusamy ML, Holmes M, Holmes TR, Shaik K, Shee K, Kiparoidze S, Smith SD, Park YA, Gomm JJ, Jones LJ, Tomás AR, Cunha AC, Selvendiran K, Hansen LA, Fersht AR, Hideg K, Gogna R, Kuppusamy P.

J Biol Chem. 2018 Mar 23;293(12):4262-4276. doi: 10.1074/jbc.RA117.000950. Epub 2018 Jan 30.

4.

Synthesis and Biological Evaluation of Curcumin-Nitroxide-Based Molecular Hybrids as Antioxidant and Anti-Proliferative Agents.

Bognar B, Kuppusamy ML, Madan E, Kalai T, Balog M, Jeko J, Kuppusamy P, Hideg K.

Med Chem. 2017;13(8):761-772. doi: 10.2174/1871520617666170522124712.

PMID:
28530545
5.

A Metal-Free Method for Producing MRI Contrast at Amyloid-β.

Hilt S, Tang T, Walton JH, Budamagunta M, Maezawa I, Kálai T, Hideg K, Singh V, Wulff H, Gong Q, Jin LW, Louie A, Voss JC.

J Alzheimers Dis. 2017;55(4):1667-1681. doi: 10.3233/JAD-160279.

6.

Exploring Structure, Dynamics, and Topology of Nitroxide Spin-Labeled Proteins Using Continuous-Wave Electron Paramagnetic Resonance Spectroscopy.

Altenbach C, López CJ, Hideg K, Hubbell WL.

Methods Enzymol. 2015;564:59-100. doi: 10.1016/bs.mie.2015.08.006. Epub 2015 Sep 8.

PMID:
26477248
7.

Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure.

Altman R, Ly S, Hilt S, Petrlova J, Maezawa I, Kálai T, Hideg K, Jin LW, Laurence TA, Voss JC.

Biochim Biophys Acta. 2015 Dec;1854(12):1860-1870. doi: 10.1016/j.bbapap.2015.09.002. Epub 2015 Sep 14.

8.

A nucleotide-independent cyclic nitroxide label for monitoring segmental motions in nucleic acids.

Nguyen PH, Popova AM, Hideg K, Qin PZ.

BMC Biophys. 2015 Apr 9;8:6. doi: 10.1186/s13628-015-0019-5. eCollection 2015.

9.

Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor.

McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, Varadharaj S, Zhang J, Hideg K, Houghton P, Kuppusamy P, Cohn DE, Selvendiran K.

Oncoscience. 2014 Mar 31;1(3):216-28. eCollection 2014.

10.

PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.

Deres L, Bartha E, Palfi A, Eros K, Riba A, Lantos J, Kalai T, Hideg K, Sumegi B, Gallyas F, Toth K, Halmosi R.

PLoS One. 2014 Jul 11;9(7):e102148. doi: 10.1371/journal.pone.0102148. eCollection 2014.

11.

PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines.

Hocsak E, Cseh A, Szabo A, Bellyei S, Pozsgai E, Kalai T, Hideg K, Sumegi B, Boronkai A.

Int J Radiat Biol. 2014 Dec;90(12):1152-61. doi: 10.3109/09553002.2014.934927. Epub 2014 Nov 14.

PMID:
24937370
12.

A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.

Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P.

PLoS One. 2014 Mar 27;9(3):e93208. doi: 10.1371/journal.pone.0093208. eCollection 2014.

13.

A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.

Magyar K, Deres L, Eros K, Bruszt K, Seress L, Hamar J, Hideg K, Balogh A, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

Biochim Biophys Acta. 2014 Jul;1842(7):935-44. doi: 10.1016/j.bbadis.2014.03.008. Epub 2014 Mar 19.

14.

Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors.

Kálai T, Altman R, Maezawa I, Balog M, Morisseau C, Petrlova J, Hammock BD, Jin LW, Trudell JR, Voss JC, Hideg K.

Eur J Med Chem. 2014 Apr 22;77:343-50. doi: 10.1016/j.ejmech.2014.03.026. Epub 2014 Mar 12.

15.

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.

Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Res. 2014 Apr 15;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. Epub 2014 Mar 3.

16.

Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.

Ravi Y, Selvendiran K, Naidu SK, Meduru S, Citro LA, Bognár B, Khan M, Kálai T, Hideg K, Kuppusamy P, Sai-Sudhakar CB.

Hypertension. 2013 Mar;61(3):593-601. doi: 10.1161/HYPERTENSIONAHA.111.00514. Epub 2013 Jan 21.

17.

Synthesis and potential use of 1,8-naphthalimide type (1)O2 sensor molecules.

Kálai T, Hideg É, Ayaydin F, Hideg K.

Photochem Photobiol Sci. 2013 Mar;12(3):432-8. doi: 10.1039/c2pp25253h.

PMID:
23160310
18.

HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.

Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.

Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.

PMID:
22801507
19.

The influence of spin-labeled fluorene compounds on the assembly and toxicity of the aβ peptide.

Petrlova J, Kálai T, Maezawa I, Altman R, Harishchandra G, Hong HS, Bricarello DA, Parikh AN, Lorigan GA, Jin LW, Hideg K, Voss JC.

PLoS One. 2012;7(4):e35443. doi: 10.1371/journal.pone.0035443. Epub 2012 Apr 30.

20.

Synthesis and study of new paramagnetic resveratrol analogues.

Kálai T, Borza E, Antus C, Radnai B, Gulyás-Fekete G, Fehér A, Sümegi B, Hideg K.

Bioorg Med Chem. 2011 Dec 15;19(24):7311-7. doi: 10.1016/j.bmc.2011.10.066. Epub 2011 Oct 28.

PMID:
22088309
21.

A rigid disulfide-linked nitroxide side chain simplifies the quantitative analysis of PRE data.

Fawzi NL, Fleissner MR, Anthis NJ, Kálai T, Hideg K, Hubbell WL, Clore GM.

J Biomol NMR. 2011 Sep;51(1-2):105-14. doi: 10.1007/s10858-011-9545-x. Epub 2011 Sep 27.

22.

Structure and dynamics of a conformationally constrained nitroxide side chain and applications in EPR spectroscopy.

Fleissner MR, Bridges MD, Brooks EK, Cascio D, Kálai T, Hideg K, Hubbell WL.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16241-6. doi: 10.1073/pnas.1111420108. Epub 2011 Sep 12.

23.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
24.

Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867.

Dayton A, Selvendiran K, Meduru S, Khan M, Kuppusamy ML, Naidu S, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2011 Nov;339(2):350-7. doi: 10.1124/jpet.111.183681. Epub 2011 Jul 28.

25.

Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity.

Kálai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K.

J Med Chem. 2011 Aug 11;54(15):5414-21. doi: 10.1021/jm200353f. Epub 2011 Jul 6.

PMID:
21702507
26.

Dynamics of tropomyosin in muscle fibers as monitored by saturation transfer EPR of bi-functional probe.

Rayes RF, Kálai T, Hideg K, Geeves MA, Fajer PG.

PLoS One. 2011;6(6):e21277. doi: 10.1371/journal.pone.0021277. Epub 2011 Jun 20.

27.

Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.

Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R.

J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e.

PMID:
21697725
28.

Synthesis and study of 2-amino-7-bromofluorenes modified with nitroxides and their precursors as dual anti-amyloid and antioxidant active compounds.

Kálai T, Petrlova J, Balog M, Aung HH, Voss JC, Hideg K.

Eur J Med Chem. 2011 Apr;46(4):1348-55. doi: 10.1016/j.ejmech.2011.01.059. Epub 2011 Feb 3.

29.

Induction of mitochondrial destabilization and necrotic cell death by apolar mitochondria-directed SOD mimetics.

Szabo A, Balog M, Mark L, Montsko G, Turi Z, Gallyas F Jr, Sumegi B, Kalai T, Hideg K, Kovacs K.

Mitochondrion. 2011 May;11(3):476-87. doi: 10.1016/j.mito.2011.01.006. Epub 2011 Feb 1.

PMID:
21292036
30.

Direct detection of free radicals and reactive oxygen species in thylakoids.

Hideg E, Kálai T, Hideg K.

Methods Mol Biol. 2011;684:187-200. doi: 10.1007/978-1-60761-925-3_16.

PMID:
20960131
31.

Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties.

Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2010 Nov 15;10(10):1027-32. doi: 10.4161/cbt.10.10.13250. Epub 2010 Nov 15.

32.

HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.

Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Res. 2010 Sep;8(9):1188-97. doi: 10.1158/1541-7786.MCR-10-0201. Epub 2010 Aug 16.

33.

Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Ther. 2010 May;9(5):1169-79. doi: 10.1158/1535-7163.MCT-09-1207. Epub 2010 May 4.

34.

Synthesis and study of new paramagnetic and diamagnetic verapamil derivatives.

Bognár B, Ahmed S, Kuppusamy ML, Selvendiran K, Khan M, Jeko J, Hankovszky OH, Kálai T, Kuppusamy P, Hideg K.

Bioorg Med Chem. 2010 Apr 15;18(8):2954-63. doi: 10.1016/j.bmc.2010.02.040. Epub 2010 Feb 25.

35.

Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling.

Khan M, Meduru S, Mostafa M, Khan S, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2010 May;333(2):421-9. doi: 10.1124/jpet.109.165175. Epub 2010 Feb 18.

36.
37.

Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Free Radic Biol Med. 2010 May 1;48(9):1228-35. doi: 10.1016/j.freeradbiomed.2010.02.009. Epub 2010 Feb 12.

38.

Site-directed spin labeling of a genetically encoded unnatural amino acid.

Fleissner MR, Brustad EM, Kálai T, Altenbach C, Cascio D, Peters FB, Hideg K, Peuker S, Schultz PG, Hubbell WL.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21637-42. doi: 10.1073/pnas.0912009106. Epub 2009 Dec 7. Erratum in: Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5693. Peuker, Sebastian [added].

39.

VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation.

Tetali SD, Budamagunta MS, Simion C, den Hartigh LJ, Kálai T, Hideg K, Hatters DM, Weisgraber KH, Voss JC, Rutledge JC.

J Lipid Res. 2010 Jun;51(6):1273-83. doi: 10.1194/jlr.M000406. Epub 2009 Dec 3.

40.

Site-specific DNA structural and dynamic features revealed by nucleotide-independent nitroxide probes.

Popova AM, Kálai T, Hideg K, Qin PZ.

Biochemistry. 2009 Sep 15;48(36):8540-50. doi: 10.1021/bi900860w.

41.

PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K.

Cardiovasc Res. 2009 Aug 1;83(3):501-10. doi: 10.1093/cvr/cvp144. Epub 2009 May 14.

PMID:
19443425
42.

Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression.

Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, Rink C, Sen CK, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2009 Jun;329(3):959-66. doi: 10.1124/jpet.108.150367. Epub 2009 Mar 10.

PMID:
19276401
43.

New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2-ylpyrroline and -tetrahydropyridine nitroxides and their precursors.

Kálai T, Balog M, Szabó A, Gulyás G, Jeko J, Sümegi B, Hideg K.

J Med Chem. 2009 Mar 26;52(6):1619-29. doi: 10.1021/jm801476y.

PMID:
19245212
44.

Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2009 May;329(2):543-50. doi: 10.1124/jpet.109.150839. Epub 2009 Feb 13.

45.

A commonly used spin label: S-(2,2,5,5-tetramethyl-1-oxyl-delta3-pyrrolin-3-ylmethyl) methanethiosulfonate.

Zielke V, Eickmeier H, Hideg K, Reuter H, Steinhoff HJ.

Acta Crystallogr C. 2008 Nov;64(Pt 11):o586-9. doi: 10.1107/S0108270108032113. Epub 2008 Oct 18.

PMID:
18989085
46.

Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction.

Mohan IK, Khan M, Wisel S, Selvendiran K, Sridhar A, Carnes CA, Bognar B, Kálai T, Hideg K, Kuppusamy P.

Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H140-51. doi: 10.1152/ajpheart.00687.2008. Epub 2008 Oct 31.

47.

Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.

Bartha E, Kiss GN, Kalman E, Kulcsár G, Kálai T, Hideg K, Habon T, Sumegi B, Toth K, Halmosi R.

J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61. doi: 10.1097/FJC.0b013e3181855cef.

PMID:
18806606
48.

Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.

Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, Anant S.

Cancer Res. 2008 Mar 15;68(6):1962-9. doi: 10.1158/0008-5472.CAN-07-6011.

49.

Structural determinants of nitroxide motion in spin-labeled proteins: solvent-exposed sites in helix B of T4 lysozyme.

Guo Z, Cascio D, Hideg K, Hubbell WL.

Protein Sci. 2008 Feb;17(2):228-39. Epub 2007 Dec 20.

50.

EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.

Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P.

J Biol Chem. 2007 Sep 28;282(39):28609-18. Epub 2007 Aug 7.

Supplemental Content

Support Center